Assenagon Asset Management
STOK icon

Assenagon Asset Management’s Stoke Therapeutics STOK Stock Holding History

Assenagon Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.9M Buy
1,128,388
+221,373
+24% +$7.1M 0.05% 294
2026
Q1 		$29.5M Sell
907,015
-320,708
-26% -$10.5M 0.04% 277
2025
Q4 		$39M Buy
1,227,723
+327,451
+36% +$9.84M 0.05% 255
2025
Q3 		$21.2M Buy
900,272
+362,299
+67% +$6.21M 0.03% 356
2025
Q2 		$6.11M Sell
537,973
-421,630
-44% -$4M 0.01% 536
2025
Q1 		$6.38M Sell
959,603
-391,322
-29% -$3.65M 0.01% 499
2024
Q4 		$14.9M Buy
1,350,925
+38,446
+3% +$472K 0.02% 409
2024
Q3 		$16.1M Sell
1,312,479
-155,723
-11% -$2.21M 0.03% 403
2024
Q2 		$19.8M Buy
+1,468,202
New +$19.8M 0.04% 287

Other funds holding STOK

GIM
Generali Investments Management Ljubljana, Slovenia $460M AUM 29.43% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
OCWP
Owl Creek Wealth Partners Denver, Colorado $342M AUM

Assenagon Asset Management's STOK Position: Q2 2026 in Review

Assenagon Asset Management increased its Stoke Therapeutics (STOK) stake by 24% in Q2 2026, buying an estimated $7.1M and bringing the position to 1,128,388 shares worth $36.9M. The position accounts for 0.05% of the portfolio, ranked #294.

Assenagon Asset Management first reported a position in STOK in Q2 2024 and has held it in 9 quarters since. The position peaked at $39M in Q4 2025. 20 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Assenagon Asset Management held 1,128,388 shares of Stoke Therapeutics worth $36.9M as of Q2 2026.
  • Assenagon Asset Management bought 221,373 Stoke Therapeutics shares in Q2 2026, an estimated $7.1M.
  • Stoke Therapeutics made up 0.05% of Assenagon Asset Management's portfolio in Q2 2026, its #294 holding.
  • Assenagon Asset Management first reported a position in Stoke Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Assenagon Asset Management's Stoke Therapeutics position peaked at $39M in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.